SNY
Sanofi
$49.48
-$0.46(-0.92%)
54
Overall
80
Value
40
Tech
44
Quality
Market Cap
$127.07B
Volume
2.44M
52W Range
$44.73 - $60.12
Target Price
$62.94
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $43.0B | $46.4B | $44.3B | ||
| Total Revenue | $45.4B | $46.4B | $44.3B | ||
| COST OF GOODS SOLD | |||||
| Cost of Revenue | $13.7B | $14.2B | $13.2B | ||
| GROSS PROFIT | |||||
| Gross Profit | $31.7B | $32.2B | $31.1B | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $19.8B | $24.0B | $21.9B | ||
| Research & Development | $6.7B | $6.7B | $7.4B | ||
| Research Expense | $6.7B | $6.7B | $7.4B | ||
| Selling, General & Administrative | $10.9B | $10.7B | $9.2B | ||
| Selling & Marketing Expenses | $10.5B | $10.7B | $9.2B | ||
| General & Administrative Expenses | $440.0M | -- | -- | ||
| Salaries & Wages | $370.0M | -- | -- | ||
| Depreciation & Amortization | $2.1B | $3.1B | $2.0B | ||
| Depreciation & Amortization | $2.1B | $3.1B | $2.0B | ||
| Amortization | $2.1B | $3.1B | $2.0B | ||
| Other Operating Expenses | $2.5B | $3.5B | $3.3B | ||
| OPERATING INCOME | |||||
| Operating income | $6.7B | $8.2B | $9.2B | ||
| EBITDA | $14.3B | -- | $11.4B | ||
| NON-OPERATING ITEMS | |||||
| Interest Expense (Non-Operating) | $461.0M | $659.0M | $1.1B | ||
| Interest Income Operating | $118.0M | -- | -- | ||
| Intinc | $206.0M | $591.0M | $519.0M | ||
| Net Non-Operating Interest Income/Expense | $288.0M | $-722.0M | $-554.0M | ||
| Other Income/Expense | $-1.2B | $-1.2B | $566.0M | ||
| Other Special Charges | $992.0M | $1.3B | $-470.0M | ||
| SPECIAL ITEMS | |||||
| Restructring And Mn A Income | $1.3B | $1.5B | $1.4B | ||
| Special Income Charges | $-777.0M | $-1.5B | $-1.4B | ||
| Impairment of Capital Assets | $-559.0M | -- | -- | ||
| PRE-TAX INCOME | |||||
| EBIT | $10.9B | -- | $7.8B | ||
| Pre-Tax Income | $10.4B | $7.2B | $6.7B | ||
| INCOME TAX | |||||
| Tax Provision | $2.0B | $1.6B | $1.1B | ||
| NET INCOME | |||||
| Net Income | $8.4B | $5.4B | $5.6B | ||
| Net Income (Continuing Operations) | $8.5B | $5.4B | $5.6B | ||
| Net Income (Discontinued Operations) | $8.4B | $5.4B | $5.6B | ||
| Net Income (Common Stockholders) | $8.4B | $5.4B | $5.6B | ||
| Normalized Income | -- | -- | $8.0B | ||
| TOTALS | |||||
| Total Expenses | $33.5B | $38.2B | $35.1B | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $1.3B | $1.3B | -- | ||
| Average Shares Outstanding (Diluted) | $1.3B | $1.3B | -- | ||
| Shares Outstanding | $1.3B | $2.5B | $2.5B | ||
| Basic EPS | -- | $4.31 | -- | ||
| Basic EPS (Continuing Operations) | -- | $4.31 | -- | ||
| Diluted EPS | -- | $4.3 | -- | ||
| Diluted EPS (Continuing Operations) | -- | $4.3 | -- | ||
| Dividend Per Share | $3.91 | $3.76 | -- | ||
| OTHER METRICS | |||||
| Acquired In Process Rn D Income | $11.1B | -- | -- | ||
| Earnings from equity interest | $68.0M | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $68.0M | -- | -- | ||
| Gain On Sale Of Business | $8.4B | -- | -- | ||
| Insurance And Claims | $440.0M | -- | -- | ||
| Interest Expense Operating | $-654.0M | -- | -- | ||
| Minority Interests | $-113.0M | $-36.0M | $-58.0M | ||
| Net Income Discontinuous Operations | -- | -- | $64.0M | ||
| Other Costof Revenue | -- | $14.2B | $13.2B | ||
| Other Gand A | $440.0M | -- | -- | ||
| Other Impairment Of Capital Assets | $216.0M | -- | -- | ||
| Selling Expense | $10.5B | -- | -- | ||
| Restruct | $1.3B | $1.5B | $1.4B | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SNY | $49.48 | -0.9% | 2.44M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |